-
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
23 Apr 2025 16:59 GMT
… Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment … Food and Drug Administration (FDA) in … cytarabine.
Additive effect with reference treatments: When used with other treatments (cytarabine … is a pharmaceutical company specializing …
-
La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue
23 Apr 2025 16:59 GMT
… désignation de médicament orphelin auprès de la Food and Drug Administration (FDA) américaine … utilisé avec d’autres traitements (cytarabine, Vidaza® ou venetoclax), AB8939 … , AB Science est une société pharmaceutique spécialisée dans la recherche, le …
-
Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML
23 Apr 2025 00:27 GMT
… for targeted precision medicine in the AML treatment paradigm.
Wang … , or low-dose cytarabine] is FDA approved for patients aged … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-approves- … , randomized, phase 2b trial. Blood. 2024;144(suppl …
-
Oncology Drug Shortages
15 Apr 2025 16:04 GMT
… pharmaceutical supply chain.
Recently, cyberattacks on drug … bacillus Calmette-Guérin, cytarabine, paclitaxel, fludarabine, … trials.
Affected Cancer Types and Alternative Treatments … Medicine. Washington, DC: The National Academies Press; 2022.
14. FDA. Drug …
-
Exicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100
15 Apr 2025 12:50 GMT
… when paired with modern AML treatment regimens, can further improve … combined with fludarabine and cytarabine to evaluate safety and … (ASCT; NCT05561751). Clinical trial results for this study are … been an early-stage biotechnology company focused on developing …
-
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
12 Apr 2025 00:04 GMT
… when paired with modern AML treatment regimens, can further improve … combined with fludarabine and cytarabine to evaluate safety and … (ASCT; NCT05561751). Clinical trial results for this study are … been an early-stage biotechnology company focused on developing …
-
[ICKSH 2025] ‘Advancing genetic insights to refine treatment strategies for Down syndrome-associated myeloid leukemia’
10 Apr 2025 09:06 GMT
… to chemotherapy agents, particularly cytarabine.
At the recent … University Graduate School of Medicine in Japan presented … prognosis more accurately and guide treatment intensity,” Ito said. … or future inclusion in trials for targeted therapies.”
…
-
Decision To Increase Medicines Access
09 Apr 2025 23:59 GMT
… facilitate access to new
treatments.
“Pharmac continues to …
combination with azacitidine or cytarabine for a type of
… medicines, better cancer management driven by
our faster cancer treatment … to provide faster cancer
treatment, with more patients receiving …
-
Pharmac To Fund Medicines For Blood Cancers, Inflammatory Bowel Disease, Eczema And Arthritis
09 Apr 2025 23:39 GMT
… combination with azacitidine or cytarabine for
a type of …
“We’re making these treatments available
for more people. … of our medicines budget to fund more treatments for
New … funding these medicines can transition to
publicly funded treatment, provided …
-
Addressing Treatment Gaps in High-Risk CML in Blast Phase
05 Apr 2025 02:47 GMT
… and Medical Oncology, Cleveland Clinic, critical gaps exist in blast-phase treatment … first-generation TKIs in separate trials: DASISION for dasatinib [NCT00481247]; ENESTnd … CML, where we borrow AML treatments like cytarabine plus venetoclax [Venclexta] or …
About
© 1995-2025